<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e> gene WT1 is overexpressed in <z:hpo ids='HP_0001909'>leukemias</z:hpo> and various types of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, and the WT1 protein was demonstrated to be an attractive target antigen for immunotherapy against these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report the outcome of a phase I clinical study of WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi>-based immunotherapy for patients with breast or <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were intradermally injected with an HLA-A*2402-restricted, natural, or modified 9-mer WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi> emulsified with Montanide ISA51 adjuvant at 0.3, 1.0, or 3.0 mg per body at 2-week intervals, with toxicity and clinical and immunological responses as the principal endpoints </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-six patients received one or more WT1 vaccinations, and 18 of the 26 patients completed WT1 vaccination protocol with three or more injections of WT1 <z:chebi fb="7" ids="16670">peptides</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity consisted only of local <z:hpo ids='HP_0010783'>erythema</z:hpo> at the WT1 vaccine injection sites in patients with breast or <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with adequate <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis, whereas severe <z:mp ids='MP_0000221'>leukocytopenia</z:mp> occurred in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with <z:mp ids='MP_0002123'>abnormal hematopoiesis</z:mp> derived from WT1-expressing, transformed hematopoietic stem cells </plain></SENT>
<SENT sid="5" pm="."><plain>Twelve of the 20 patients for whom the efficacy of WT1 vaccination could be assessed showed clinical responses such as reduction in leukemic blast cells or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> sizes and/or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers </plain></SENT>
<SENT sid="6" pm="."><plain>A clear correlation was observed between an increase in the frequencies of WT1-specific cytotoxic T lymphocytes after WT1 vaccination and clinical responses </plain></SENT>
<SENT sid="7" pm="."><plain>It was therefore demonstrated that WT1 vaccination could induce WT1-specific cytotoxic T lymphocytes and result in <z:e sem="disease" ids="C0920421" disease_type="Neoplastic Process" abbrv="">cancer regression</z:e> without damage to <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
</text></document>